Mode
Text Size
Log in / Sign up
Phase 2 Completed N=121 Randomized Double-blind Treatment

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

Source: ClinicalTrials.gov NCT03077165 ↗
Enrolled (actual)
121
Serious AEs
3.3%
Results posted
Oct 2020
Primary outcomePrimary: Relative Reduction of Reference Ulcer Area After 4 Weeks of Treatment on Top of Standard of Care Compared With Baseline Reference Ulcer Area (W000) Assessed During Study Visits — -52.85; -46.42; -31.07; -43.33 cm2

Summary

Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.

Outcome Measures

OutcomeResultp-value
PRIMARY
Relative Reduction of Reference Ulcer Area After 4 Weeks of Treatment on Top of Standard of Care Compared With Baseline Reference Ulcer Area (W000) Assessed During Study Visits
-52.85; -46.42; -31.07; -43.33; -41.10; -41.23
SECONDARY
Adverse Events
SECONDARY
Assessment of Laboratory Parameters

Eligibility Criteria

Inclusion Criteria

  • Caucasian (defined for this study as having 2 Caucasian parents), men or women
  • Age ≥ 18 years old
  • 18.5 kg/m2 ≤ BMI ≤ 45.0 kg/m2 (= Weight (kg) / height² (m²))
  • Patients with chronic venous disease documented by imaging to detect a venous disorder in one or both the sub- and extra-fascial venous systems. The examination performed within 6 months before selection can be used.
  • Patients with at least one active venous leg ulcer localised in the gaiter area (CEAP C6) diagnosed or reoccurred for more than 6 weeks and less than 2 years at selection and 3 cm away from other ulcers. Patients with bilateral ulcerations or multiple ulcerations on one or both legs are eligible for selection.
  • Size of Reference Ulcer (defined as the largest ulcer in size that is fitting the area selection criteria) should be ≥ 5 cm2 and ≤ 100 cm2 at the selection visit and ≥ 4.5 cm2 and ≤ 100 cm2 at the inclusion visit (measured by transparent sheet and confirmed with the digital 3D imaging device).
  • Ankle Brachial Pressure Index (ABPI) ≥ 0.8 and ≤ 1.3 measured by Doppler ultrasound.

Exclusion Criteria

  • Unlikely or unwilling to be compliant to standardized compression recommendation, study medication and visits, previous records of poor compliance to compression stockings.
  • Inadequately controlled type 1 and type 2 diabetes with an HbA1c > 8%.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03077165). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search